...the decision to stop the Phase I trial is consistent with its focus on solid tumors.Sihuan...
...span cancer, infectious diseases and metabolic disorders.  Financial terms were not disclosed. Xuanzhu is a unit of Sihuan Pharmaceutical Holdings Group Ltd....

...Shanghai:600267) to treat influenza infection and a clinical trial application from the company for COVID-19. Sihuan Pharmaceutical Holdings Group Ltd....

...CMO and James Samuels as CFO. Li was VP of clinical development and CMO at Sihuan Pharmaceutical Holdings Group Ltd....

...Co. Inc. markets Atelec clinidipine, a long-acting dual L/N type calcium channel blocker, for hypertension. Sihuan Pharmaceutical Holdings Group Ltd....

...RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover...
...RaQualia. The companies could not be reached for details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Sihuan Pharmaceutical Holdings Group Ltd....

...patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), gastric and colorectal cancers. Sihuan Pharmaceutical Holdings Group Ltd....

...additional animal models of AD. Mitsubishi Tanabe Pharma Corp. markets Radicut edaravone to treat stroke. Sihuan Pharmaceutical Holdings Group Ltd....

...KBP5209 ) to treat advanced solid tumors including non-small cell lung, gastric and colorectal cancers. Sihuan...
...with Covance, the contract research subsidiary of Laboratory Corp. of America Holdings (NYSE:LH), to develop Sihuan's...

...research unit to develop Sihuan’s pipeline candidates. Covance will provide preclinical and clinical research services. Sihuan...
...The companies declined to disclose financial terms. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Sihuan Pharmaceutical Holdings Group Ltd....